Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
1 hedge funds and large institutions have $35M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
78% more capital invested
Capital invested by funds: $19.7M → $35M (+$15.3M)
0% more funds holding
Funds holding: 1 → 1 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$356K |
Top Sellers
BHVN Hedge Fund Activity: Q2 2026 in Review
1 of the 8,334 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2026, worth a combined $35M — up 78% from $19.7M a quarter earlier.
Fund positioning in BHVN was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Knoll Capital Management, adding an estimated $356K.
- 1 institutional investor held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $35M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2026, up 78% quarter-over-quarter.
- 0 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2026 and 0 closed out.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2026 was Knoll Capital Management, an estimated $356K added.
Based on aggregated 13F filings for Q2 2026.